Home >> Marketplace Directory >> E. histolytica diagnostic test, 8/17

E. histolytica diagnostic test, 8/17

image_pdfCreate PDF

 

August 2017—Techlab Inc. received FDA clearance for its E. Histolytica Quik Chek test, a rapid diagnostic test that specifically detects pathogenic E. histolytica and does not cross-react with nonpathogenic Enta­moeba dispar. The test, which targets an adhesin protein unique to E. histolytica, is designed to aid clinicians in the diagnosis of amebiasis. It can be paired with the Giardia/Cryptosporidium Quik Chek test to provide a complete triple parasite screen.

In a separate release, the company announced it showcased its C. Diff Quik Chek Complete at the American Society for Microbiology Microbe 2017 meeting in New Orleans. According to the company, it’s the only test that simultaneously detects and differentiates glutamate dehydrogenase antigen and toxins A and B of Clostridium difficile on a single device.

Techlab, 540-953-1664

CAP TODAY
X